Clinical Trial Update: Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers long-term follow-up of patients who received EG110A, a non-replicative HSV-1–derived gene therapy, in Phase 1/2 studies. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Spinal Cord Injury

Drugs mentioned

• EG110A

Snippet

Sponsor: EG 427 | Conditions: Urinary Bladder, Overactive, Spinal Cord Injury | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING